overseas tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Compounding pharmacies can resume making
Description
Long-acting formulations extending beyond once-weekly dosing could improve adherence further
*Nature Metabolism*, 3(2), 189200
New Dual Incretin Agonist for Type 2 Diabetes This first-in-class, once-weekly injectable agent has demonstrated significant positive outcomes in reducing A1C and weight in clinical trials
The medication primarily targets metabolic pathways through GIP and GLP-1 receptors, which are widely expressed in pancreatic tissue, the gastrointestinal tract, adipose tissue, and certain brain regions involved in appetite regulation
If no, stop and contact your prescriber or pharmacist before drawing any medication
Manufactured by Eli Lilly, the medication is indicated for weight management and weight-related complications such as sleep apnea
